In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Deepak Bhatt
Speaker
Deepak Bhatt
Deepak Bhatt Deepak Bhatt

Brigham and Women's Hospital, Boston (United States of America)

Specialities : Interventional Cardiology , Acute Coronary Syndromes, Peripheral Vascular and Cerebrovascular Disease, Pharmacology and Pharmacotherapy, Risk Factors and Prevention

Deepak L. Bhatt MD, MPH, FACC, FAHA, FSCAI, FESC, is Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital Heart & Vascular Center and Professor of Medicine at Harvard Medical School. He is also a Senior Physician at Brigham and Women’s Hospital. After graduating as valedictorian from Boston Latin School, Dr. Bhatt obtained his undergraduate science degree as a National Merit Scholar at the Massachusetts Institute of Technology while also serving as a research associate at Harvard Medical School. He received his medical doctorate from Cornell University and a Master in Public Health with a concentration in clinical effectiveness from Harvard University. His internship and residency in internal medicine were at the Hospital of the University of Pennsylvania, and his cardiovascular training was at Cleveland Clinic, where he also completed fellowships in interventional cardiology and cerebral and peripheral vascular intervention.

38 presentations from this speaker

Lessons from REDUCE-IT: How will the results impact practice?

Event : ESC Congress 2020

  • Session : Novel opportunities tackling residual cardiovascular Risk: The evolving role of triglycerides
  • Speaker : D Bhatt (Newton,US)
  • Organised by PACE-CME, supported by Amarin in the form of an educational grant

REDUCE-IT: outcomes by baseline statin type

Event : ESC Congress 2020

  • Session : Pharmacology and Pharmacotherapy ePosters
  • Speaker : D Bhatt (Newton,US)

Does high-dose fish oil reduce cardiovascular events via triglycerides?

Event : ESC Congress 2019

  • Session : Targeting triglycerides to prevent coronary artery disease
  • Speaker : D Bhatt (Newton,US)

Omega-3s in the cardiology clinic - Practical implications and strategies to improve care

Event : ESC Congress 2019

  • Session : Residual risk for cardiovascular disease - Omega-3 fatty acids in cardiology practice
  • Speaker : D Bhatt (Newton,US)
  • Organised by Medscape Education, supported with an educational grant from Amarin

Omega-3s in the cardiology clinic - Practical implications and strategies to improve care.

Event : ESC Congress 2019

  • Session : Reducing residual risk for cardiovascular disease - Omega-3 fatty acids in cardiology practice
  • Speaker : D Bhatt (Newton,US)
  • Organised by Medscape Education, supported with an independent educational grant from Amarin

Panel discussion and questions and answers session

Event : ESC Congress 2019

  • Session : Residual risk for cardiovascular disease - Omega-3 fatty acids in cardiology practice
  • Speaker : D Bhatt (Newton,US)
  • Organised by Medscape Education, supported with an educational grant from Amarin

Panel discussion and questions and answers session

Event : ESC Congress 2019

  • Session : Reducing residual risk for cardiovascular disease - Omega-3 fatty acids in cardiology practice
  • Speaker : D Bhatt (Newton,US)
  • Organised by Medscape Education, supported with an independent educational grant from Amarin

THEMIS/THEMIS-PCI

Event : ESC Congress 2019

  • Session : Meet the trialist - THEMIS/THEMIS PCI
  • Speaker : P Steg (Paris,FR), D Bhatt (Newton,US)

Welcome and introductions

Event : ESC Congress 2019

  • Session : Residual risk for cardiovascular disease - Omega-3 fatty acids in cardiology practice
  • Speaker : D Bhatt (Newton,US)
  • Organised by Medscape Education, supported with an educational grant from Amarin

Welcome and introductions

Event : ESC Congress 2019

  • Session : Reducing residual risk for cardiovascular disease - Omega-3 fatty acids in cardiology practice
  • Speaker : D Bhatt (Newton,US)
  • Organised by Medscape Education, supported with an independent educational grant from Amarin

Anticoagulation should replace antiplatelets in CAD prevention - Chairperson conclusion.

Event : ESC Congress 2018

  • Session : The great debate: thrombocardiology post COMPASS.
  • Speaker : D Bhatt (Newton,US)
  • Great Debate

Chairman’s welcome and introduction: the mandate for improving residual cardiovascular disease risk reduction in patients with adversely elevated LDL-C

Event : ESC Congress 2018

  • Session : PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease
  • Speaker : D Bhatt (Newton,US)
  • Sponsored by Sanofi US and Regeneron Pharmaceuticals

Closing remarks - Setting the COMPASS into new directions - Who will benefit most in coronary artery disease?

Event : ESC Congress 2018

  • Session : Setting the COMPASS into new directions - Who will benefit most in coronary artery disease?
  • Speaker : D Bhatt (Newton,US)
  • Sponsored by Bayer AG

Getting real world and “hands on” in patients with elevated LDL-C and high risk features for atherosclerotic cardiovascular disease — Case management sessions.

Event : ESC Congress 2018

  • Session : PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease
  • Speaker : D Bhatt (Newton,US)
  • Sponsored by Sanofi US and Regeneron Pharmaceuticals

Interactive question and answer session - PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease.

Event : ESC Congress 2018

  • Session : PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease
  • Speaker : D Bhatt (Newton,US)
  • Sponsored by Sanofi US and Regeneron Pharmaceuticals

Opening remarks - Setting the COMPASS into new directions - Who will benefit most in coronary artery disease?

Event : ESC Congress 2018

  • Session : Setting the COMPASS into new directions - Who will benefit most in coronary artery disease?
  • Speaker : D Bhatt (Newton,US)
  • Sponsored by Bayer AG

Primary cardiovascular prevention: understanding international guidelines.

Event : ESC Congress 2018

  • Session : Who needs aspirin? Finding your patient in the world’s guidelines
  • Speaker : D Bhatt (Newton,US)
  • Sponsored by Bayer AG

Aspirin for life - PRO

Event : ESC Congress 2017

  • Session : Aspirin for life
  • Speaker : D Bhatt (Newton,US)

Aspirin for life - Rebuttal PRO

Event : ESC Congress 2017

  • Session : Aspirin for life
  • Speaker : D Bhatt (Newton,US)

Dual antiplatelet therapy beyond 12 months?

Event : ESC Congress 2017

  • Session : Pharmacotherapy after STEMI: current concepts
  • Speaker : D Bhatt (Newton,US)

Interactive discussions and questions - Vascular protection in CAD and PAD through factor Xa inhibition... The COMPASS study.

Event : ESC Congress 2017

  • Session : Vascular protection in coronary artery disease (CAD) and peripheral artery disease (PAD) through factor Xa inhibition... The COMPASS study
  • Speaker : D Bhatt (Newton,US), P Steg (Paris,FR), J Eikelboom (Hamilton,CA), SJ Connolly (Hamilton,CA), S Yusuf (Hamilton,CA)
  • Sponsored by Bayer AG

State of the Art: P2Y12 inhibitors in acute coronary syndromes

Event : ESC Congress 2017

  • Session : P2Y12 inhibitors in acute coronary syndromes
  • Speaker : D Bhatt (Newton,US)

Which patients with CAD or PAD are at the highest risk of cardiovascular events... What do the registries teach us.

Event : ESC Congress 2017

  • Session : Exploring vascular protection in patients with coronary artery disease (CAD) or peripheral artery disease (PAD) through the potential of factor Xa inhibition... The COMPASS study
  • Speaker : P Steg (Paris,FR), D Bhatt (Newton,US)
  • Sponsored by Bayer AG

Aggressive LDL-C lowering to impact plaque burden: what is the evidence demonstrating?

Event : ESC Congress 2016

  • Session : The state of the science of LDL-C lowering in patients with coronary atherosclerosis
  • Speaker : C Ballantyne (Houston,US), D Bhatt (Newton,US), SJ Nicholls (Adelaide,AU)
  • Sponsored by PeerVoice

Evaluating the relationship between plaque burden and CV events in coronary atherosclerosis.

Event : ESC Congress 2016

  • Session : The state of the science of LDL-C lowering in patients with coronary atherosclerosis
  • Speaker : SJ Nicholls (Adelaide,AU), C Ballantyne (Houston,US), D Bhatt (Newton,US)
  • Sponsored by PeerVoice

Optimizing treatment for patients with coronary atherosclerosis: translating the evidence into practical strategies.

Event : ESC Congress 2016

  • Session : The state of the science of LDL-C lowering in patients with coronary atherosclerosis
  • Speaker : D Bhatt (Newton,US), C Ballantyne (Houston,US), SJ Nicholls (Adelaide,AU)
  • Sponsored by PeerVoice

Q&A: managing coronary atherosclerosis in practice.

Event : ESC Congress 2016

  • Session : The state of the science of LDL-C lowering in patients with coronary atherosclerosis
  • Speaker : C Ballantyne (Houston,US), D Bhatt (Newton,US), SJ Nicholls (Adelaide,AU)
  • Sponsored by PeerVoice

Welcome & introduction: clinical considerations for patients with coronary atherosclerosis in today's practice.

Event : ESC Congress 2016

  • Session : The state of the science of LDL-C lowering in patients with coronary atherosclerosis
  • Speaker : D Bhatt (Newton,US)
  • Sponsored by PeerVoice

Balancing ischaemia reduction with bleeding risks: what's optimal?

Event : ESC Congress 2014

  • Session : Novel approaches to managing and studying patients with acute coronary syndrome
  • Speaker : D Bhatt (Newton,US)

Introduction - New frontiers in cholesterol management in high CV risk patients.

Event : ESC Congress 2014

  • Session : New frontiers in cholesterol management in high cardiovascular risk patients
  • Speaker : D Bhatt (Newton,US)
  • Sponsored by Sanofi Regeneron

Novel trials and new horizons with dabigatran: protecting patients at high risk of cardiac events and stroke.

Event : ESC Congress 2014

  • Session : Novel trials and new horizons with dabigatran: protecting patients at high risk of cardiac events and stroke
  • Speaker : D Bhatt (Newton,US)
  • Sponsored by Boehringer Ingelheim

The role of factor Xa inhibition in ACS patients with and without atrial fibrillation: safe and effective use of factor Xa inhibition within the framework of triple antithrombotic therapy.

Event : ESC Congress 2014

  • Session : New advances and practical dimensions of optimizing management of acute coronary syndrome: evidence-based use of oral factor Xa inhibition to improve outcomes in patients with acute coronary syndrome (ACS) - Risk stratification, patient selection, and clinical pearls for oral factor Xa-based management
  • Speaker : D Bhatt (Newton,US)
  • Sponsored by Bayer HealthCare

Adjunctive reperfusion therapies in primary percutaneous coronary intervention: is there an optimal strategy?

Event : ESC Congress 2013

  • Session : ST-elevation myocardial infarction 2013
  • Speaker : D Bhatt (Newton,US)

SAVOR-TIMI 53: Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 Study

Event : ESC Congress 2013

  • Session : Hot Line III: Late Breaking Trials on Risk factors and Diabetes
  • Speaker : D Bhatt (Newton,US)

SAVOR-TIMI 53: Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus.

Event : ESC Congress 2013

  • Session : Meet the trialist: SAVOR-TIMI 53 Study
  • Speaker : D Bhatt (Newton,US)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are